drugset / Trial / NCT05274139
Treatment of Primary CNS Lymphoma ( FTD )
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of FTD regiment (fotemustine, temozolomide and dexamethasone ) for patients with primary CNS lymphoma.
Timeline
- Start
- 2017-03-02
- Primary completion
- 2019-03-02
- Completion
- 2019-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 1 g | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | fotemustine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | metrotrexate | Unknown | 3.5 g | Intravenous |